Literature DB >> 11351307

Immunohistochemical analysis of NY-ESO-1 antigen expression in normal and malignant human tissues.

A A Jungbluth1, Y T Chen, E Stockert, K J Busam, D Kolb, K Iversen, K Coplan, B Williamson, N Altorki, L J Old.   

Abstract

NY-ESO-1, a member of the CT (cancer/testis) family of antigens, is expressed in normal testis and in a range of human tumor types. Knowledge of NY-ESO-1 expression has depended on RT-PCR detection of mRNA and there is a need for detecting NY-ESO-1 at the protein level. In the present study, a method for the immunochemical detection of NY-ESO-1 in paraffin-embedded tissues has been developed and used to define the expression pattern of NY-ESO-1 in normal tissues and in a panel of human tumors. No normal tissue other than testis showed NY-ESO-1 reactivity, and expression in testis was restricted to germ cells particularly spermatogonia. In human tumors, the frequency of NY-ESO-1 antigen expression corresponds with past analysis of NY-ESO-1 mRNA expression e.g., 20-30% of lung cancers, bladder cancers and melanoma, and no expression in colon and renal cancer. Co-typing of NY-ESO-1 antigen and mRNA expression in a large panel of lung cancers showed a good correlation. There is great variability in NY-ESO-1 expression in individual tumors, ranging from an infrequent homogeneous pattern of staining to highly heterogeneous antigen expression. Copyright 2001 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11351307     DOI: 10.1002/ijc.1282

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  124 in total

1.  Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab.

Authors:  Jianda Yuan; Matthew Adamow; Brian A Ginsberg; Teresa S Rasalan; Erika Ritter; Humilidad F Gallardo; Yinyan Xu; Evelina Pogoriler; Stephanie L Terzulli; Deborah Kuk; Katherine S Panageas; Gerd Ritter; Mario Sznol; Ruth Halaban; Achim A Jungbluth; James P Allison; Lloyd J Old; Jedd D Wolchok; Sacha Gnjatic
Journal:  Proc Natl Acad Sci U S A       Date:  2011-09-20       Impact factor: 11.205

Review 2.  Cancer/testis antigens and urological malignancies.

Authors:  Prakash Kulkarni; Takumi Shiraishi; Krithika Rajagopalan; Robert Kim; Steven M Mooney; Robert H Getzenberg
Journal:  Nat Rev Urol       Date:  2012-06-19       Impact factor: 14.432

3.  Epigenetic modulation of MAGE-A3 antigen expression in multiple myeloma following treatment with the demethylation agent 5-azacitidine and the histone deacetlyase inhibitor MGCD0103.

Authors:  Amberly Moreno-Bost; Susann Szmania; Katie Stone; Tarun Garg; Antje Hoerring; Jackie Szymonifka; John Shaughnessy; Bart Barlogie; H Grant Prentice; Frits van Rhee
Journal:  Cytotherapy       Date:  2010-12-20       Impact factor: 5.414

4.  A panel of cancer-testis genes exhibiting broad-spectrum expression in haematological malignancies.

Authors:  Amanda P Liggins; Seah H Lim; Elizabeth J Soilleux; Karen Pulford; Alison H Banham
Journal:  Cancer Immun       Date:  2010-08-23

5.  Blockade of Programmed Death 1 Augments the Ability of Human T Cells Engineered to Target NY-ESO-1 to Control Tumor Growth after Adoptive Transfer.

Authors:  Edmund K Moon; Raghuveer Ranganathan; Evgeniy Eruslanov; Soyeon Kim; Kheng Newick; Shaun O'Brien; Albert Lo; Xiaojun Liu; Yangbing Zhao; Steven M Albelda
Journal:  Clin Cancer Res       Date:  2015-08-31       Impact factor: 12.531

6.  Expression and clinical significance of MAGE and NY-ESO-1 cancer-testis antigens in adenoid cystic carcinoma of the head and neck.

Authors:  Johannes A Veit; Daniela Heine; Julia Thierauf; Jochen Lennerz; Subasch Shetty; Patrick J Schuler; Theresa Whiteside; Dirk Beutner; Moritz Meyer; Inga Grünewald; Gerd Ritter; Sacha Gnjatic; Andrew G Sikora; Thomas K Hoffmann; Simon Laban
Journal:  Head Neck       Date:  2016-02-13       Impact factor: 3.147

7.  The role of MAGEA2 in head and neck cancer.

Authors:  Chad A Glazer; Ian M Smith; Sheetal Bhan; Wenyue Sun; Steven S Chang; Kavita M Pattani; William Westra; Zubair Khan; Joseph A Califano
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2011-03

Review 8.  [Expression of cancer testis (CT) antigens in pediatric and adolescent melanomas].

Authors:  N Behrendt; T Schultewolter; K Busam; D Frosina; G Spagnoli; A Jungbluth
Journal:  Pathologe       Date:  2017-07       Impact factor: 1.011

9.  Decitabine facilitates immune recognition of sarcoma cells by upregulating CT antigens, MHC molecules, and ICAM-1.

Authors:  Deepa Kolaseri Krishnadas; Lei Bao; Fanqi Bai; Satheesh Cheeyancheri Chencheri; Kenneth Lucas
Journal:  Tumour Biol       Date:  2014-03-02

10.  CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit.

Authors:  Jianda Yuan; Sacha Gnjatic; Hao Li; Sarah Powel; Humilidad F Gallardo; Erika Ritter; Geoffrey Y Ku; Achim A Jungbluth; Neil H Segal; Teresa S Rasalan; Gregor Manukian; Yinyan Xu; Ruth-Ann Roman; Stephanie L Terzulli; Melanie Heywood; Evelina Pogoriler; Gerd Ritter; Lloyd J Old; James P Allison; Jedd D Wolchok
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-12       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.